The trial, called HIV-CORE 0052, aims to evaluate the safety, tolerability, and immunogenicity of the HIVconsvX vaccine, the university said. The project is part of the European Aids Vaccine Initiative, funded by the European Commission.
The jab is known as a “mosaic,” meaning it can target a broad range of HIV-1 variants and potentially become a suitable vaccine for use around the world.
Scientists will give two doses of the vaccine four weeks apart to 13 healthy, HIV-negative adults, aged between 18 and 65, who are not considered at risk of infection.
Mosaic means “Associated with Moses” and we see 13 individuals ( Number of Rebellion). It’s another MRNA jab.. Beware!!
40 years wait and the release..Another God Wink related to Egypt letting go of God’s ppl though..
Prepare for the Coming of the Lord!
Please repent and accept the free gift of Jesus Christ’s death on the cross for payment for your sins..